共 122 条
[1]
Sacco RL(1996)A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE steering committee Lancet 348 1329-1339
[2]
Diener HC(2008)Aspirin and extended-release dipyridamole versus clopidogrel for recurrent stroke N Engl J Med 359 1238-1251
[3]
Yusuf S(2009)The Essen stroke risk score predicts recurrent cardiovascular events: a validation within the reduction of Atherothrombosis for continued health (REACH) registry Stroke. 40 350-354
[4]
Cotton D(2004)Clopidogrel resistance: a new chapter in a fast-moving story Circulation. 109 3064-3067
[5]
Ounpuu S(2019)Clopidogrel Pharmacogenetics Circ Cardiovasc Interv 12 354-362
[6]
Lawton WA(2009)Cytochrome p-450 polymorphisms and response to clopidogrel N Engl J Med 360 363-375
[7]
Weimar C(2009)Genetic determinants of response to clopidogrel and cardiovascular events N Engl J Med 360 1039-1046
[8]
Diener HC(2018)Clinical outcomes of CYP2C19 genotype-guided antiplatelet therapy: existing evidence and future directions Pharmacogenomics. 19 70-78
[9]
Alberts MJ(2016)Association between CYP2C19 loss-of-function allele status and efficacy of Clopidogrel for risk reduction among patients with minor stroke or transient ischemic attack JAMA. 316 21-33
[10]
Steg PG(2017)Genetic polymorphisms and Clopidogrel efficacy for acute ischemic stroke or transient ischemic attack: a systematic review and meta-analysis Circulation 135 419-426